Patient Experience Data in Non‑Interventional Studies Supporting EMA Marketing Authorisation Applications between 2018 and 2023

28/05/2026
28/05/2026
EU PAS number:
EUPAS1000001011
Study
Ongoing
Study type

Study topic

Other

Study topic, other

Patient Experience Data

Study type

Not applicable
Study design details

Study design

Retrospective descriptive analysis

Main study objective

The primary objective of this study is to characterise the use of PED in non‑interventional NIS submitted to support regulatory decision‑making within initial marketing authorisation applications (MAAs) and extensions of indication (EoIs) incorporating real‑world data (RWD) and assessed by the European Medicines Agency (EMA) between 2018 and 2023. This includes describing the regulatory lifecycle stage (pre‑ or post‑authorisation), study design, objectives, data sources, and the types of PED collected, as well as the instruments and methodologies used

Setting

Not applicable

Interventions

Not applicable

Comparators

Not applicable

Outcomes

Not applicable

Data analysis plan

Regulatory documents of eligible submissions were screened to identify NIS including PED, as well as patient engagement (PE) activities. Data were extracted on study and PED characteristics. Descriptive statistics will be used to summarise the characteristics of PED use across the identified NIS. Quantitative variables will be analysed descriptively, including counts, percentages, means and medians. Statistical analyses will be performed using Excel

Summary results

250 applications were screened. 42 (17%) submissions included PED in NIS or PE activities. Most of these submissions concerned antineoplastic and immunomodulating agents and frequently involved orphan medicinal products. Across all these submissions, a total of 47 NIS using PED and 6 PE activities were identified, with most NIS conducted in the post authorisation setting, often as additional pharmacovigilance activities. PROs were the most common form of PED, primarily assessing quality of life, while patient preference studies were less frequently used.